The current study is important in that it provides the first clinical data investigating the effects of adding short-term metformin to GnRH antagonists on follicular fluid redox markers and pro-inflammatory cytokine production in CC-resistant PCOS patients. The gene discussed is GNRH1; the disease is polycystic ovary syndrome.